Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV, Kirsch B, Bhatt DL, Budaj A, Coppolecchia R, Eikelboom J, James SK, Jones WS, Merkely B, Keller L, Hermanides RS, Campo G, Ferreiro JL, Shibasaki T, Mundl H, Alexander JH; PACIFIC AMI Investigators. Rao SV, et al. Among authors: hermanides rs. Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27. Circulation. 2022. PMID: 36030390 Clinical Trial.
High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.
Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW. Hermanides RS, et al. Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20. Heart. 2011. PMID: 20962338 Clinical Trial.
Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
Hermanides RS, Ottervanger JP, ten Berg JM, Gosselink AT, van Houwelingen G, Dambrink JH, Stella PR, Hamm C, van 't Hof AW; On-TIME 2 Trial Investigators. Hermanides RS, et al. J Invasive Cardiol. 2012 Mar;24(3):84-9. J Invasive Cardiol. 2012. PMID: 22388296 Free article. Clinical Trial.
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial.
Tavenier AH, Hermanides RS, Fabris E, Lapostolle F, Silvain J, Ten Berg JM, Lassen JF, Bolognese L, Cantor WJ, Cequier Á, Chettibi M, Goodman SG, Hammett CJ, Huber K, Janzon M, Merkely B, Storey RF, Zeymer U, Ecollan P, Collet JP, Willems FF, Diallo A, Vicaut E, Hamm CW, Montalescot G, van 't Hof AWJ; ATLANTIC investigators. Tavenier AH, et al. Among authors: hermanides rs. Thromb Haemost. 2020 Jan;120(1):65-74. doi: 10.1055/s-0039-1700546. Epub 2019 Nov 21. Thromb Haemost. 2020. PMID: 31752042 Clinical Trial.
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis.
Claassens DMF, Bergmeijer TO, Vos GJA, Hermanides RS, van 't Hof AWJ, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, Asselbergs FW, Mosterd A, Herrman JR, Dewilde WJM, Janssen PWA, Kelder JC, Mahmoodi BK, Deneer VHM, Ten Berg JM. Claassens DMF, et al. Among authors: hermanides rs. Circ Cardiovasc Interv. 2021 Apr;14(4):e009434. doi: 10.1161/CIRCINTERVENTIONS.120.009434. Epub 2021 Mar 16. Circ Cardiovasc Interv. 2021. PMID: 33722066
Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial.
Tavenier AH, Claassens DMF, Hermanides RS, Vos GJA, Bergmeijer TO, Kelder JC, Deneer VHM, van 't Hof AWJ, Ten Berg JM. Tavenier AH, et al. Among authors: hermanides rs. Catheter Cardiovasc Interv. 2022 Feb;99(3):676-685. doi: 10.1002/ccd.29861. Epub 2021 Jul 7. Catheter Cardiovasc Interv. 2022. PMID: 34233065 Clinical Trial.
Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights From the COMBINE OCT-FFR Trial.
Fabris E, Berta B, Roleder T, Hermanides RS, IJsselmuiden AJJ, Kauer F, Alfonso F, von Birgelen C, Escaned J, Camaro C, Kennedy MW, Pereira B, Magro M, Nef H, Reith S, Roleder-Dylewska M, Gasior P, Malinowski K, De Luca G, Garcia-Garcia HM, Granada JF, Wojakowski W, Kedhi E. Fabris E, et al. Among authors: hermanides rs. Circ Cardiovasc Interv. 2022 May;15(5):e011728. doi: 10.1161/CIRCINTERVENTIONS.121.011728. Epub 2022 Apr 29. Circ Cardiovasc Interv. 2022. PMID: 35485232
Fractional Flow Reserve-Negative High-Risk Plaques and Clinical Outcomes After Myocardial Infarction.
Mol JQ, Volleberg RHJA, Belkacemi A, Hermanides RS, Meuwissen M, Protopopov AV, Laanmets P, Krestyaninov OV, Dennert R, Oemrawsingh RM, van Kuijk JP, Arkenbout K, van der Heijden DJ, Rasoul S, Lipsic E, Rodwell L, Camaro C, Damman P, Roleder T, Kedhi E, van Leeuwen MAH, van Geuns RM, van Royen N. Mol JQ, et al. Among authors: hermanides rs. JAMA Cardiol. 2023 Nov 1;8(11):1013-1021. doi: 10.1001/jamacardio.2023.2910. JAMA Cardiol. 2023. PMID: 37703036
89 results